ArticleComputational and structural biotechnology journal2019
Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer.
Article in Computational and structural biotechnology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Metabolic reprogramming in tumor-associated cells of hematologic malignancies: mechanisms, crosstalk networks, and therapeutic implications in the tumor microenvironment.Frontiers in immunology · 2026Review
- Integrating Single-Cell and Bulk RNA Sequencing Data to Explore Sphingolipid Metabolism Molecular Signatures in Ovarian Cancer Prognosis: an Original Study.International journal of medical sciences · 2025Article
- Sphingolipids in prostate cancer prognosis: integrating single-cell and bulk sequencing.Aging · 2024Article
- Article
- Microenvironmental and cell intrinsic factors governing human cDC2 differentiation and monocyte reprogramming.Frontiers in immunology · 2023Article
- Singularity and Commonality in Response to SARS-CoV-2 in Lung and Colon Cell Models.International journal of molecular sciences · 2022Article
- Keep a Little Fire Burning-The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity.International journal of molecular sciences · 2022Review
- Infiltration of LPAR5Frontiers in immunology · 2022Article
- Lysophosphatidate Promotes Sphingosine 1-Phosphate Metabolism and Signaling: Implications for Breast Cancer and Doxorubicin Resistance.Cell biochemistry and biophysics · 2021Article
- Lysophosphatidic Acid Signaling in Cancer.Cancers · 2020Article
- Article
- Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma.Annals of translational medicine · 2020Article
- Regulation of Tumor Immunity by Lysophosphatidic Acid.Cancers · 2020Review
- Sphingolipidomics in Translational Sepsis Research-Biomedical Considerations and Perspectives.Frontiers in medicine · 2020Review
- Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.Cancers · 2019Review
- MicroRNA-30 inhibits the growth of human ovarian cancer cells by suppressing RAB32 expression.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 4 countries.
Funding
Abstract
The sphingolipid and lysophosphatidate regulatory networks impact diverse mechanisms attributed to cancer cells and the tumor immune microenvironment. Deciphering the complexity demands implementation of a holistic approach combined with higher-resolution techniques. We implemented a multi-modular integrative approach consolidating the latest accomplishments in gene expression profiling, prognostic/predictive modeling, next generation digital pathology, and systems biology for epithelial ovarian cancer. We assessed patient-specific transcriptional profiles using the sphingolipid/lysophosphatidate/immune-associated signature. This revealed novel sphingolipid/lysophosphatidate-immune gene-gene associations and distinguished tumor subtypes with immune high/low context. These were characterized by robust differences in sphingolipid-/lysophosphatidate-related checkpoints and the drug response. The analysis also nominates novel survival models for stratification of patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.